Prostate cancer – a biomarker perspective

le Liu, Yanqiu, Hegde, Priti, Zhang, Fengmin, Hampton, Garret, Jia, Shidong
Foilsithe 2012

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

le Patil, Namrata S., Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S.
Foilsithe in PLoS One (2021)

NF-κB Mediates the Stimulation of Cytokine and Chemokine Expression by Human Articular Chondrocytes in Response to Fibronectin Fragments

le Pulai, Judit I., Chen, Hong, Im, Hee-Jeong, Kumar, Sanjay, Hanning, Charles, Hegde, Priti S., Loeser, Richard F.
Foilsithe 2005

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer

le Li, Yijin, Vennapusa, Bharathi, Chang, Ching-Wei, Tran, David, Nakamura, Rin, Sumiyoshi, Teiko, Hegde, Priti, Molinero, Luciana
Foilsithe in Appl Immunohistochem Mol Morphol (2021)

Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer

le Itatani, Yoshiro, Yamamoto, Takamasa, Zhong, Cuiling, Molinolo, Alfredo A., Ruppel, Jane, Hegde, Priti, Taketo, M. Mark, Ferrara, Napoleone
Foilsithe in Proc Natl Acad Sci U S A (2020)

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer

le Ziai, James, Huseni, Mahrukh, Foreman, Oded, Eastham-Anderson, Jeffrey, Xiao, Yuanyuan, Chu, Felix, Kowanetz, Marcin, Hegde, Priti S, Kim, Jeong
Foilsithe in J Immunother Cancer (2014)

Evidence‐Based Development and Clinical Use of Precision Oncology Therapeutics

le Comment, Leah A., Ward, Ashley F., Schrock, Alexa B., Fabrizio, David, Venstrom, Jeffrey M., Hegde, Priti S., Alexander, Brian M.
Foilsithe in Clin Pharmacol Ther (2020)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers

le Rozenblit, Mariya, Huang, Richard, Danziger, Natalie, Hegde, Priti, Alexander, Brian, Ramkissoon, Shakti, Blenman, Kim, Ross, Jeffrey S, Rimm, David L, Pusztai, Lajos
Foilsithe in J Immunother Cancer (2020)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

le Molinero, Luciana, Li, Yijin, Chang, Ching-Wei, Maund, Sophia, Berg, Maureen, Harrison, Jeanne, Fassò, Marcella, O’Hear, Carol, Hegde, Priti, Emens, Leisha A.
Foilsithe in J Immunother Cancer (2019)

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

le Xia, Wenle, Bacus, Sarah, Hegde, Priti, Husain, Intisar, Strum, Jay, Liu, Leihua, Paulazzo, Georgina, Lyass, Ljuba, Trusk, Patricia, Hill, Jason, Harris, Jennifer, Spector, Neil L.
Foilsithe 2006

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models

le Huseni, Mahrukh, Totpal, Klara, Du, Changchun, Dalpozzo, Katie, Zhu, Jing, Rishipathak, Deepali, McNamara, Erin, Jonshtone, Bernadette, Hegde, Priti S, Rhee, Ina, Damico-Beyer, Lisa, Kim, Jeong
Foilsithe in J Immunother Cancer (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models

le Huseni, Mahrukh, Totpal, Klara, Du, Changchun, Dalpozzo, Katie, Zhu, Jing, Rishipathak, Deepali, McNamara, Erin, Jonshtone, Bernadette, Hegde, Priti S, Rhee, Ina, Damico-Beyer, Lisa, Kim, Jeong
Foilsithe in J Immunother Cancer (2014)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

le Fehlings, Michael, Jhunjhunwala, Suchit, Kowanetz, Marcin, O’Gorman, William E., Hegde, Priti S., Sumatoh, Hermi, Lee, Boon Heng, Nardin, Alessandra, Becht, Etienne, Flynn, Susan, Ballinger, Marcus, Newell, Evan W., Yadav, Mahesh
Foilsithe in J Immunother Cancer (2019)

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer...

le von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Foilsithe in Oncologist (2018)

BI-22 CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (...

le Phillips, Heidi, Sandmann, Thomas, Li, Congfen, Cloughesy, Timothy, Chinot, Olivier L., Wick, Wolfgang, Nishikawa, Ryo, Mason, Warren, Henriksson, Roger, Saran, Frank, Lai, Albert, Moore, Nicola, Hegde, Priti, Abrey, Lauren, Bourgon, Richard, Garcia, Josep, Bais, Carlos
Foilsithe in Neuro Oncol (2014)

Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer

le Jarzabek, Monika A., Proctor, William R., Vogt, Jennifer, Desai, Rupal, Dicker, Patrick, Cain, Gary, Raja, Rajiv, Brodbeck, Jens, Stevens, Dale, van der Stok, Eric P., Martens, John W. M., Verhoef, Cornelis, Hegde, Priti S., Byrne, Annette T., Tarrant, Jacqueline M.
Foilsithe in PLoS One (2018)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

le Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Foilsithe in J Immunother Cancer (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

le Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Foilsithe in J Immunother Cancer (2015)

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin

le Woodhouse, Ryan, Li, Meijuan, Hughes, Jason, Delfosse, David, Skoletsky, Joel, Ma, Pei, Meng, Wei, Dewal, Ninad, Milbury, Coren, Clark, Travis, Donahue, Amy, Stover, Dan, Kennedy, Mark, Dacpano-Komansky, Jennifer, Burns, Christine, Vietz, Christine, Alexander, Brian, Hegde, Priti, Dennis, Lucas
Foilsithe in PLoS One (2020)

Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing

le Zhang, Liangxuan, Chen, Liangjing, Sah, Sachin, Latham, Gary J., Patel, Rajesh, Song, Qinghua, Koeppen, Hartmut, Tam, Rachel, Schleifman, Erica, Mashhedi, Haider, Chalasani, Sreedevi, Fu, Ling, Sumiyoshi, Teiko, Raja, Rajiv, Forrest, William, Hampton, Garret M., Lackner, Mark R., Hegde, Priti, Jia, Shidong
Foilsithe 2014